Reviewer's report

Title: Fibrinogen concentrate administration attributes to significant reductions of blood loss and transfusion requirements in thoracic aneurysm repair

Version: 2 Date: 11 March 2014

Reviewer: Tiziano Porretta

Reviewer's report:

Major Compulsory Revisions:
In my opinion the manuscript don't need major revisions.

Discretionary Revisions:
Please note that four Fibrinogen Concentrates are currently available: Haemocomplettan (CSL Behring, Marburg, Germany), Fibrinogene T1 and Clottagen (LFB, Les Ulis, France), Fibrinogen HT (Benesis, Osaka, Japan) and FibroRaas (Shangai RAAS, Shangai, China). However, the most widely used is Haemocomplettan (commercialised in the USA as Ria-STAP), and a large number of studies have evaluated the effects of fibrinogen supplementation in patients suffering from various forms of congenital and acquired hypofibrinogemia. The use of Fibrinogen HT in the clinical study limits the possibility of comparison with similar trials.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
'I declare that I have no competing interests'